TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
ERAS

Erasca Inc

Healthcare · Biotechnology

14.10$ -2.1% vs. previous close Closing price · As of: Nov 2, 2026

Ownership

Ownership Structure

Who owns Erasca Inc (ERAS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 73.0% of the shares are freely tradable; institutional investors hold 93.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 93.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 10.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 73.0%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 11.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 350Mio.

Largest Shareholders

Institutions

Institutions ERAS
Name Stake (%) Shares Change (%) Date
Frazier Life Sciences Management, L.P. 7.14 24,975,188 +1.2 06/30/2026
T. Rowe Price Investment Management,Inc. 6.06 21,185,839 -0.3 06/30/2026
BlackRock Inc 6.05 21,154,146 +5.0 06/30/2026
RTW INVESTMENTS, LLC 5.13 17,946,754 +11.1 06/30/2026
VR Adviser, LLC 5.12 17,891,812 +9.2 06/30/2026
State Street Corp 3.48 12,184,555 +31.0 06/30/2026
Logos Global Management LP 3.47 12,150,000 +9.0 06/30/2026
Vanguard Capital Management, LLC 3.26 11,402,199 +1.4 06/30/2026
Siren, L.L.C. 3.26 11,397,781 +1.4 06/30/2026

Funds

Funds ERAS
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.90 10,139,138 +3.4 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?